Cargando…
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
Introduction: OnabotulinumtoxinA (BT-A) is a preventive treatment for chronic migraine (CM), which needs to be administered regularly by a trained clinician every 3 months. The spread of the severe acute respiratory syndrome coronavirus-2 pandemic has forced many patients to momentarily stop the sch...
Autores principales: | Baraldi, Carlo, Ornello, Raffaele, Favoni, Valentina, Sacco, Simona, Caponnetto, Valeria, Pierangeli, Giulia, Pani, Luca, Cevoli, Sabina, Guerzoni, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082239/ https://www.ncbi.nlm.nih.gov/pubmed/33935945 http://dx.doi.org/10.3389/fneur.2021.647995 |
Ejemplares similares
-
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023) -
P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
por: Guerzoni, Simona, et al.
Publicado: (2015) -
Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017) -
Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2018) -
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)